Japan's Ministry of Health, Labour and Welfare (MHLW) publishes lists of every medical institution that has filed a plan to provide regenerative treatment. Counting the 2026 versions of those lists, there are 6,781 treatment plans from about 4,464 institutions, spread across all 47 prefectures. Tokyo has 1,519 institutions, about a third of the national total, and Osaka is second with 537; together they account for close to half.

That tells you where the choice is widest. It does not tell you which clinic is right for you. The check that matters for a patient is narrower: has this clinic filed a plan for the exact treatment you would receive?

Where the numbers come from

Japan's Act on the Safety of Regenerative Medicine took effect in November 2014. Before a hospital or clinic offers a regenerative treatment, such as stem cells, immune cells or platelet-rich plasma (PRP), it must have a provision plan for that treatment reviewed by a certified committee and then submit the plan to the government. Class I and Class II plans go to a specially certified committee; Class III plans can go to a certified committee that reviews only Class III. The full framework is explained in Regenerative Medicine in Japan: How the Safety Act Works and the Three Risk Classes.

The MHLW publishes three lists of institutions that have filed treatment plans, one for each risk class. Each row gives the institution's name, prefecture, address and the name of the treatment. This article counts those rows as follows:

  • Snapshot dates. The three lists were taken from archived copies of different dates: Class I on July 19, 2026, Class II on September 26, 2026, and Class III on May 18, 2026. The lists change as plans are filed, amended or withdrawn, so the figures describe those dates.
  • Plans. Each row counts as one plan. An institution that has filed separate plans for different treatments appears on several rows.
  • Institutions. Rows are de-duplicated by name, prefecture and address. An institution with both a Class II and a Class III plan counts once.
  • Neighborhood counts. Figures for names such as Ginza or Umeda are the number of institutions whose address contains that name.
  • Research is excluded. The lists cover treatment plans only. Regenerative medicine offered as clinical research is not in them.

By prefecture: Tokyo and Osaka far ahead

The ten prefectures with the most institutions:

Aerial view of a dense city skyline with a large park and distant mountains

Rank Prefecture Institutions Treatment plans
1 Tokyo 1,519 2,568
2 Osaka 537 887
3 Kanagawa 305 400
4 Fukuoka 235 368
5 Aichi 214 322
6 Hyogo 171 250
7 Saitama 158 202
8 Chiba 146 188
9 Hokkaido 92 151
10 Kyoto 79 129

Next come Hiroshima (62), Shizuoka (60), Gunma (52), Tochigi (50) and Nagano (43).

A few things stand out:

  • Tokyo alone has more institutions than the prefectures ranked 2 through 6 combined (1,462). It also holds about 38% of all treatment plans.
  • The top eight prefectures together have 3,285 institutions, more than 70% of the total. They map closely onto the Tokyo, Osaka, Nagoya and Fukuoka metropolitan areas.
  • 6,781 plans across about 4,464 institutions works out to roughly 1.5 plans per institution, so many institutions have filed plans for more than one treatment.

By risk class: Class II is more concentrated in Tokyo

The three classes differ a great deal in size and in where they are filed:

Class Plans Institutions Leading prefectures by plans
Class I (high risk) 7 7 Hokkaido, Miyagi, Tokyo, Aichi, Kyoto, Osaka and Fukuoka, 1 each
Class II (medium risk) 2,515 1,601 Tokyo 1,172; Osaka 383; Fukuoka 144
Class III (low risk) 4,259 3,427 Tokyo 1,395; Osaka 503; Kanagawa 304

Class I has just 7 treatment plans, one in each of 7 prefectures. All were filed by university hospitals and similar large hospitals, and all are for the same treatment: allogeneic islet transplantation for insulin-dependent diabetes.

Class II includes treatments that use cultured stem cells, such as a patient's own fat-derived stem cells. Tokyo holds about 47% of Class II plans, and Tokyo and Osaka together hold more than 60%. That is a much tighter concentration than in Class III, where Tokyo's share is about 33%. Fukuoka ranks third nationally for Class II plans, ahead of Aichi and Kanagawa.

Class III is the largest group and typically includes most autologous immune cell therapies. It is more spread out: Kanagawa, Fukuoka, Aichi, Hyogo, Chiba and Saitama each have more than 100 Class III plans.

If you add the institution counts for the three classes, you get 5,035, which is 571 more than the de-duplicated 4,464. The difference is institutions that appear on more than one list. In other words, one clinic can have a Class II plan for one treatment and a Class III plan for another, which is why any check has to be made treatment by treatment.

Tokyo: Chuo and Minato wards lead

After standardizing the way addresses are written, the Tokyo wards with the most institutions are:

Nighttime view of a busy multi-lane city street lined with tall, brightly lit commercial buildings.

Ward Institutions
Chuo 347
Minato 300
Shibuya 125
Shinjuku 110
Chiyoda 103
Setagaya 55
Toshima 55
Meguro 49

Chuo, Minato, Shibuya, Shinjuku and Chiyoda together have 985 institutions, about two-thirds of Tokyo's total.

By neighborhood name, 285 institutions have "Ginza" in their address, the highest of the names counted here. Addresses in the Omotesando area are usually written as Jingumae: 35 institutions have Jingumae in their address and 9 have Omotesando. Shibuya appears in 125 addresses and Shinjuku in 117.

Osaka: Kita and Chuo wards

Of Osaka Prefecture's 537 institutions, 132 are in Osaka City's Kita Ward and 94 in its Chuo Ward, together about 40% of the prefecture. By neighborhood, 63 addresses contain Umeda and 56 contain Shinsaibashi. Outside Osaka City, Sakai (23) and Suita (18) have the most.

What the map does and does not tell you

Clinics cluster in central Tokyo and Osaka because that is where Japan's large cities, medical resources and patient demand are. The clustering does not show that care in one area is better, or that clinics in one area are more compliant. For a patient coming from the United States or elsewhere, the distribution is useful in two ways: Tokyo and Osaka give you the widest range for comparing similar treatments, and the lists mix large hospitals with small specialist clinics, which differ a great deal in what they offer.

A dense cityscape framed by tall glass buildings, with a large construction site and cranes in the midground, a rooftop terrace in the foreground, and distant hills under a partly cloudy sky.

What decides whether a clinic is a good fit is the following:

  • The plan matches the treatment. Plans are filed per treatment. A clinic may have filed a Class III plan for a PRP treatment but no Class II plan for intravenous stem cells. Check the exact procedure you are being offered.
  • The class matches the cells. Cells from someone other than the patient, such as donated umbilical cord cells, are Class I under the rules. Cultured fat-derived stem cells from your own body are generally Class II. If a clinic's description and the class in its plan don't line up, ask why. How to Tell Whether a Japanese Regenerative Medicine Clinic Is Compliant walks through these checks.
  • Your health fits the treatment. Healthy adults interested in anti-aging (stem cells, exosomes, NK cells) or knee treatment can ask us directly. If you have any medical condition, or you are under 18, pregnant or planning a pregnancy, have advanced cancer or are on chemotherapy or radiotherapy, or have serious heart, brain or blood vessel disease or a psychiatric condition, a Japanese doctor first needs to review your medical records.

You can hand the checking to us. Send the clinic's name and the treatment to our advisors, and we'll check whether it has filed a provision plan for that treatment and whether the class matches. To browse institutions by area and class, see our clinic directory; for what to ask at a consultation, see 10 Questions to Ask a Japanese Clinic Before Regenerative Treatment.

Stem Cell Japan provides consultation and coordination for regenerative medicine in Japan; treatment is provided by Japanese medical institutions. Our advisors work directly with Japanese hospitals and clinics, match you with a suitable doctor and hospital, and arrange medical record translation, a remote video consultation, interpretation during your visit and follow-up after you return home. Consultation and coordination are free. You can start with our pre-screening.

Frequently asked questions

Where in Japan are most regenerative medicine clinics?

Tokyo has the most. Counting the MHLW lists with duplicates removed, Tokyo has 1,519 institutions, about a third of the national total, followed by Osaka (537), Kanagawa (305), Fukuoka (235) and Aichi (214).

Which Tokyo neighborhoods have the most clinics?

Chuo and Minato wards, with 347 and 300 institutions. Shibuya, Shinjuku and Chiyoda each have more than 100. Those five wards hold about two-thirds of Tokyo's institutions, and 285 institutions have Ginza in their address.

Why is the number of plans higher than the number of institutions?

Because plans are filed per treatment. An institution that offers several treatments files a plan for each, so it appears on several rows. The 6,781 treatment plans come from about 4,464 institutions.

Is a clinic in Tokyo or Osaka a safer choice?

Location alone doesn't tell you that. A large cluster means more options to compare. What you need to confirm is that the clinic has filed a plan for your exact treatment, that its risk class matches, and that a Japanese doctor finds the treatment suitable for your health.

Will these numbers change?

Yes. The lists are updated as institutions file, amend or withdraw plans. The figures here come from archived lists dated May, July and September 2026 and describe those dates.

Sources: MHLW e-Saisei published lists of Class I, Class II and Class III regenerative medicine provision plans (treatment), archived July 19, September 26 and May 18, 2026; MHLW, "Regenerative medicine, cell medicine and gene therapy" policy page; Act on the Safety of Regenerative Medicine (Act No. 85 of 2013) and its Enforcement Regulations. Checked November 2026; MHLW publications prevail.

Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.